Sector: Life Sciences

Latest content

Leahy aims to reverse USPTO’s discretionary denials in new PTAB reform bill

It is unclear whether the legislation will muster the level of support in Congress to make it onto the statute books

22 September 2021

NPE litigation in the US bounces back

The Long Read: Sector-by-sector analysis reveals that transport, financial services and networking all recorded triple-digit percentage growth in patent suits filed by non-practising entities between 2018 and 2020, writes IAM data reporter Bridget Diakun

22 September 2021

FDA seeks USPTO action to tackle patent thicketing

IP policies proposed by the Department of Health miss the mark, but discussions between the two agencies get closer to the nub of the issue

21 September 2021

Bausch Health pays $300 million to settle pay-for-delay class action

The agreement demonstrates the huge sums at stake in reverse payment disputes

17 September 2021

CAFC decision highlights continued danger of inequitable conduct rulings

The Federal Circuit’s judgment in a recent pharma patent case is a stark reminder that IP professionals must remain vigilant

16 September 2021

$8 billion Sobi takeover shows orphan drug IP assets are in high demand

The acquisition of the rare disease specialist is latest development in the booming orphan drug deals market

14 September 2021

New Humira decision changes venue selection playbook for US biosimilar patent disputes

A recent court ruling suggests that plaintiffs will enjoy more latitude on venue selection when suing biologics imitators

14 September 2021

The DABUS decision makes Australia look like a champion of innovation, not a chump

Saturday Opinion: Federal Court's AI inventorship decision should serve as a clarion call for Australia to lead on innovation issues

11 September 2021

Biologics patent thicketing problem getting worse, says Fresenius’ IP chief

The growing IP estates of new drugs such as Keytruda give an idea of the mounting challenges for US biosimilars, claims Rachel Moodie

09 September 2021

Life science leaders

Featured in Special Report 2021 Q3: IP leadership - what it is and why it matters

09 September 2021

Get unlimited access to all IAM content